Date:1/25/2011

roblems damage our reputation for high quality production, the effects of competition on sales of our innovative products, especially Copaxone® (including potential generic and oral competition for Copaxone®), the impact of continuing consolidation of our distributors and customers, our ability to identify, consummate and successfully integrate acquisitions (including the acquisition of ratiopharm), interruptions in our supply chain or problems with our information technology systems that adversely affect our complex manufacturing processes, intense competition in our specialty pharmaceutical businesses, any failures to comply with the complex Medicare and Medicaid reporting and payment obligations, our exposure to currency fluctuations and restrictions as well as credit risks, the effects of reforms in healthcare regulation, adverse effects of political or economical instability, major hostilities or acts of terrorism on our significant worldwide operations, increased government scrutiny in both the U.S. and Europe of our agreements with brand companies, dependence on the effectiveness of our patents and other protections for innovative products, our ability to achieve expected results through our innovative R&D efforts, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, uncertainties surrounding the legislative and regulatory pathway for the registration and approval of biotechnology-based products, potentially significant impairments of intangible assets and goodwill, potential increases in tax liabilities resulting from challenges to our intercompany arrangements, our potential exposure to product liability claims to the extent not covered by insurance, the termination or expiration of governmental programs or tax benefits, current economic conditions, any failure to retain key personnel or to attract additional executive and managerial talent, environmental risks and
'/>"/>

SOURCE Teva Respiratory LLC, a subsidiary of Teva Pharmaceutical Industries Ltd. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. PolyGel® Receives SADMERC Approval for L-Code L3670 for ThermoActive™ Cold & Hot Mobile Compression Shoulder Orthosis
2. PolyGel® Receives SADMERC Approval for L-Code L0627 for New ThermoActive™ Plus Cold & Hot Compression Lumbar Orthosis
3. State Launches Immunize for Good Marketing Campaign to Remind Parents Immunizations are Safe and the Best Way to Prevent Childhood Illness
4. Oklahoma City Thunder Point Guard Russell Westbrook and NBA Legend Bob Lanier Join Vaccines for Teens Educational Campaign to Urge Local Teens to Take Their Best Shot at Health
5. Medela Announces Virtual Human Milk Collection Campaign Award Recipients in Honor of 2010 Prematurity Awareness Month
6. PCMA: Independent Drugstore Lobby Continues Disclosure Double Standard Transparency Campaign
7. Lilly Surpasses United Way 2010 Campaign Goal
8. 7,000 Bracelets For Hope™ - A Rare Disease Awareness Campaign
9. RxDrugSAFE™ Featured in National Campaign by Purdue Pharma and NCPA
10. Pfizer Offers First 500,000 Consumers Free Advil® to Launch Medicine Cabinet Cleanout Campaign
11. In Honor of American Pharmacists Month, Sams Club® Pharmacies Host October Awareness Campaign Including Free Medication Check-Ups